Lymphatropic Combination Therapy
Time: 2:00 pm
day: Day Two
Details:
- Targeting MAPK and PI3K/mTOR pathways is critical due to crosstalk
- Combination therapy strategies have been hampered by dose-limiting toxicities
- A Lymphatropic single agent orally bioavailable mutikinase inhibitor provides a path forward